En español

AIDS Workgroup

What We Do:

The NIDA AIDS Workgroup facilitates the coordination of HIV/AIDS activities across the different divisions/centers/offices within NIDA. This workgroup has representatives from all of the divisions/centers/offices at NIDA and reflects the broad research areas that are supported by NIDA. Members of the workgroup are listed along with their programmatic interests. E-mail addresses are listed for program staff in the divisions to which AIDS applications are assigned. Please feel free to contact the appropriate program staff to discuss potential applications.


Center for Clinical Trials Network (CCTN)

  • Petra Jacobs - NIDA/CCTN HIV/AIDS Liaison

Division of Neuroscience and Behavior (DNB)

  • Roger Sorensen - investigations of the neuropathology and neurological disorders caused by drug abuse and HIV/AIDS, including interactions of drugs of abuse, host and viral factors on neuronal and glial function, neuroplasticity, and the neuropathogenesis of neuronal, cognitive, and motor deficits due to drug abuse and HIV infection.
  • Yu Lin - cognitive, neuropsychological and neurobiological sequelae of HIV/AIDS; neuroinflammation; and co-morbidity.
  • Minda Lynch - laboratory-based animal investigations of the cognitive and behavioral antecedents for high-risk sexual behavior; and behavioral and cognitive consequences of HIV/AIDS.
  • Vishnu Purohit - systems biology approach for research on HIV-Associated Neurological Disorders [HAND] with drug abuse and antiretroviral therapy (ART), the impact of drugs of abuse in the development of HIV latency/ reservoirs in the brain, and the development of new technologies to increase the penetration of the brain-vascular system by ART).

Division of Epidemiology, Services, and Prevention Research (DESPR)

  • Elizabeth Lambert - behavioral and social epidemiology and natural history research on HIV/AIDS and other infectious diseases among drug users, their social networks, and their communities; behavioral and molecular epidemiology of host and viral factors that increase risks for the acquisition and transmission of HIV and co-infections, including drug-resistant viruses.
  • Richard Jenkins - behavioral and social aspects of preventive biomedical trials;; community, structural, and policy-level prevention interventions; international HIV prevention; innovative research methods and multi-method research designs; preventive intervention with men who have sex with men; prevention interventions with co-morbid populations.
  • Dionne Jones - treatment services for HIV/AIDS patients, including women and minorities and those at risk of infection; HIV/AIDS interventions and health and behavioral outcomes.
  • Jeff Schulden - the association between psychiatric illness and substance abuse among adults, with a particular focus on the association between substance abuse and PTSD, trauma, and stress; intimate partner violence and substance use disorders; suicide and overdose; and comorbid mental health and substance use disorders among persons living with HIV.
  • Shoshana Kahana - behavioral interventions for comorbid conditions, specifically traumatic stress and drug use, in adolescent and adult populations; integrating HIV risk reduction into drug abuse treatment; and the development and effective implementation of interventions that promote treatment adherence in populations with chronic health conditions, including HIV.

Division of Therapeutics and Medical Consequences of Drug Abuse (DTMC)

  • Jag Khalsa - medical/clinical consequences of drug abuse and co-occurring infections including HIV, hepatitis (HCV), STDs, TB, and others; interactions between drugs of abuse and medications used in the treatment of drug addiction.
  • Guifang Lao - medical/clinical consequences of drug abuse and co-occurring infections including HIV, hepatitis C/B, and STDs/STIs; developing innovative research program of non-invasive techniques/methodologies for studying the medical consequences of drug abuse and co-occurring HIV, hepatitis and others infections.
  • Will Aklin – Neurobehavioral processes underlying HIV risk (impulsivity and risky decision-making) as treatment targets, behavioral and integrative treatments for HIV, integration of risk reduction strategies into drug abuse treatment, treatments that promote adherence to HIV medications

International Program (IP)

  • Steve Gust - international activities related to characterizing the links between drug abuse and HIV/AIDS, including its transmission and prevention

Intramural Research Program (IRP)

  • Karran Phillips - mobile health (mHealth) approaches to the integration of addiction treatment with HIV and HCV risk reduction and HIV, HCV, and primary care

Office of Science Policy and Communications (OSPC)

  • Michele L. Rankin


This page was last updated October 2016

Get this Publication

    NIDA AIDS Research Program, click here
    National HIV/AIDS Strategy